Johnson & Johnson (JNJ) on Q3 2020 Results - Earnings Call Transcript

Oct. 13, 2020 4:20 PM ETJohnson & Johnson (JNJ)2 Comments
SA Transcripts profile picture
SA Transcripts
133.95K Followers

Johnson & Johnson (NYSE:JNJ) Q3 2020 Results Conference Call October 13, 2020 8:30 AM ET

Company Participants

Chris DelOrefice - VP, IR

Joe Wolk - Executive Vice President, Chief Financial Officer

Jennifer Taubert - Executive Vice President and Worldwide Chairman, Pharmaceuticals

Ashley McEvoy - Executive Vice President and Worldwide Chairman, Medical Devices

Thibaut Mongon - Executive Vice President and Worldwide Chairman, Consumer Health

Mathai Mammen - Global Head of Janssen Research & Development

Conference Call Participants

David Lewis - Morgan Stanley

Chris Schott - JPMorgan

Larry Biegelsen - Wells Fargo

Josh Jennings - Cowen & Co

Danielle Antalffy - SVB Leerink

Terence Flynn - Goldman Sachs

Louise Chen - Cantor Fitzgerald

Operator

Good morning, and welcome to Johnson & Johnson's Third Quarter 2020 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This call is being recorded. [Operator Instructions]

I would now like to turn the conference call over to Johnson & Johnson. You may begin.

Chris DelOrefice

Good morning. This is Chris DelOrefice, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the third quarter of 2020. I hope everyone is healthy and continues to remain safe during these times. Joining me on today’s call is Joe Wolk, Executive Vice President, Chief Financial Officer. During the Q&A portion of the call, we will be joined by Jennifer Taubert, Executive Vice President and Worldwide Chairman, Pharmaceuticals; Ashley McEvoy, Executive Vice President and Worldwide Chairman, Medical Devices; Thibaut Mongon, Executive Vice President and Worldwide Chairman, Consumer Health; and Mathai Mammen, Global Head of Janssen Research & Development.

A few logistics before we get into the details. This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.